ENTA
USDEnanta Pharmaceuticals Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$7.565
最高
$8.470
最低
$7.475
交易量
0.24M
公司基本面
市值
169.9M
行業
生物科技
國家
United States
交易統計
平均交易量
0.20M
交易所
NMS
貨幣
USD
52週範圍
相關新聞
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24
JMP Securities analyst Roy Buchanan maintains Enanta Pharma with a Market Outperform and raises the price target from $23 to $24.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's
